PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Millions of people in the EU are negatively affected by cancer, and cancer is one of the leading causes of death and morbidity in Europe (ecis.jrc.europa.eu). The PRIME-ROSE consortium will contribute to the Mission Cancer goal to optimise treatment and support quality of life of more than 3 million people by 2030.The PRIME-ROSE consortium envisions to support Mission Cancer through the following objectives: 1) increase access to optimised and affordable treatment interventions for cancer patients that prolong life and increase quality of life, 2) generate clinical evidence and evaluate effectiveness in Precision Cancer Medicine (PCM)-relevant and synthetically randomised, controlled academic investigator-initiated pragmatic clinical trials, and 3) work together across Europe with relevant experts to implement evidence-based PCM in routine practice and address inequalities in access.This consortium builds on the truly bottom-up, clinician-initiated family of DRUP-like innovative trials that provide broad access to precision medicine for cancer patients.This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.